Navigation Links
InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
Date:8/6/2009

ucted by Shionogi & Co. Ltd. in Japan.
  • Pirfenidone was safe and generally well tolerated in both CAPACITY studies. There was no difference in SAEs and fewer deaths were observed with pirfenidone compared to placebo. Adverse events were comparable to previous clinical studies of pirfenidone.
  • New, pre-specified exploratory efficacy data from CAPACITY pertaining to dose-effect relationships, mean change in FVC volume and Six-Minute Walk Test distance that was presented provided valuable insight into the estimate of treatment effect in the combined populations.
  • ITMN-191:

    • InterMune announced today the successful completion of chronic toxicology studies in two specific species: a six-month chronic toxicology study in rats and a nine-month chronic toxicology study in monkeys. There were no significant drug-related findings in either study. These results provide the necessary preclinical data to conduct the intended Phase 2 and Phase 3 clinical programs for ITMN-191.
    • InterMune expects that the first patient will be enrolled in August in the Phase 2b study of ITMN-191 in combination with standard of care. The Phase 2b trial will study both twice-daily (600mg and 900mg q12h) and three-times-daily regimens (300mg q8h) and both 12-week and 24-week treatment durations.
    • InterMune and its collaboration partner Roche announced today their plan to initiate during the third quarter, a Phase 1b multiple-ascending-dose (MAD) study of once-daily and twice-daily ITMN-191 co-administered with a low dose of ritonavir in combination with standard dose Pegasys(R) (peginterferon alfa-2a) and Copegus(R) (ribavirin) in HCV-infected patients. Ritonavir is an antiviral compound commonly used at low doses to enhance or "boost" the pharmacokinetic (PK) profiles of several marketed HIV protease inhibitors and at least one
      '/>"/>

    SOURCE InterMune, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

    Related biology technology :

    1. InterMune to Release Second Quarter Financial Results on August 6
    2. InterMune to Present at Goldman Sachs Healthcare Conference
    3. InterMune Reports First Quarter 2009 Financial Results and Business Highlights
    4. InterMune to Release First Quarter Financial Results on April 30
    5. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
    6. InterMune to Present at Canaccord Adams Hepatitis C Conference
    7. InterMune to Present at Citis 4th Annual Biotech Day
    8. InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
    9. InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
    10. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
    11. InterMune Announces Issuance of U.S. Patent for ITMN-191
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/22/2014)... China , 22 juli 2014 BGI ... BGI, ,s wereld grootste organisatie op het gebied van ... service ten behoeve van hele menselijke genoomsequentie via het ... In 2013 acquireerde BGI Complete Genomics, ... staat vanwege de in eigen beheer ontwikkelde sequentietechnologieën met ...
    (Date:7/22/2014)... In chemical and petrochemical plants, ... sight. The rapid rise of TDL analyzers over ... as a core gas measurement technology, and their ... the gas analyzer technology of choice for many ... some processes have limited their application range. METTLER ...
    (Date:7/22/2014)... Seattle, WA (PRWEB) July 22, 2014 Quorum ... a new service for large clinical trials called Quick ... and is designed to address the research industry’s need for ... The service is available for studies planning 50 or ... with a combined planned North American site count of 80 ...
    (Date:7/22/2014)... Juli 2014 Qforma, ein führender Anbieter ... von Marcus Bergler zum General Manager ... europäischen kommerziellen Aktivitäten von Qforma bereits als Vice ... anschloss, war er in Positionen als VP Vertrieb ... Deutschland bei IMS Health und als Direktor bei ...
    Breaking Biology Technology:BGI Tech introduceert service op gebied van hele menselijke exoomsequencing op geavanceerd Complete Genomics-platform 2METTLER TOLEDO Shows How Tunable Diode Lasers (TDLs) Can Be Installed Where No TDLs Have Gone Before 2Quorum Review IRB Launches New Quick Step™ Service for Large Clinical Trials 2Quorum Review IRB Launches New Quick Step™ Service for Large Clinical Trials 3Qforma gibt Schaffung des neuen Postens als General Manager in Europa bekannt 2
    ... Red Herring has announced,that ProGenTech Limited was a winner of the ... technology companies based in Asia. , ... Asia and identified the top 100 out of more than 1,000,closely ... "It is truly an honor ...
    ... the U.S. Patent and Trademark Office has ... for Traumatic Injury to the Nervous System”, ... University of Florida with the company as ... method of determining the presence of neural ...
    ... Inc.,(Nasdaq: BNVI ) will present findings on the ... Annual San Antonio Breast Cancer Symposium,being held at the Henry ... Bionovo,s poster presentation will ... BN107. As explained by Dr. Emma Shtivelman,Director of Cancer Research ...
    Cached Biology Technology:Red Herring Awards ProGenTech Limited for the 2008 Red Herring Asia 100 2 Banyan Biomarkers Announces Issuance of U.S. Patent for Biomarkers for Traumatic Injury 2Bionovo to Present Recent Findings of BN107, its Anticancer Agent, at the 31st Annual San Antonio Breast Cancer Symposium 2
    (Date:7/22/2014)... allergic to dust mites (and chances are you are), ... the University of Iowa have developed a vaccine that ... immune response. In animal tests, the nano-sized vaccine package ... to the allergens, according to the paper, published in ... Journal . One big reason why it works, ...
    (Date:7/22/2014)... Health Policy and Economics have linked tighter Medicaid ... for schizophrenic individuals. , The study comes amid ... actually save money, when other costs are taken ... extra approval step before tests or treatments can ... prior authorization is intended to encourage physicians ...
    (Date:7/22/2014)... be on the horizon. Bacteria that produce a ... insulin resistance and other adverse effects of a ... discovered., "Of course it,s hard to speculate from ... Ph.D., assistant professor of Pharmacology. "But essentially we,ve ... in mice, even though they,re eating a high-fat ...
    Breaking Biology News(10 mins):Researchers create vaccine for dust-mite allergies 2Are state Medicaid policies sentencing people with mental illnesses to prison? 2Vanderbilt study shows therapeutic bacteria prevent obesity in mice 2
    ... lice treatments such as the pyrethroids cypermethrin and deltamethrin, ... increased from 2008 to 2009, although use of emamectine ... again due to resistance problems, e.g. azametiphos, diflubenzuron and ... 1997, was also used again in 2009, mainly under ...
    ... The National Foundation for Cancer Research announced today ... the Department of Molecular and Experimental Medicine at The ... of the 5th Annual Szent-Gyrgyi Prize for Progress in ... on a humble chicken virus in the early 1960s, ...
    ... older than previously thought, says a new analysis of the ... plants, or angiosperms, first arose 140 to 190 million years ... Proceedings of the National Academy of Sciences pushes back ... 25 to 75 million years earlier than either the fossil ...
    Cached Biology News:5th Annual Szent-Györgyi Prize for Progress in Cancer Research awarded 25th Annual Szent-Györgyi Prize for Progress in Cancer Research awarded 3Molecular study could push back angiosperm origins 2Molecular study could push back angiosperm origins 3
    ... is fast emerging as a powerful new ... Until now, only amino groups have been ... reagents such as our Sulfo-SBED. Sulfhydryl-reactive Mts-Atf-Biotin ... exciting additions to the protein interaction tool ...
    ... is specifically designed as a high tech ... variable mass compensation allows high shaking speed ... aeration and, therefore, faster growth and higher ... ideal when high reproducibility is critical ...
    ... cocktail of 3 siRNAs specifically targeted to ... popular product. The siTrio reagent guarantees you ... target gene when used under standard conditions ... of optimal transfection with one of B-Bridges ...
    ... MULTI-FUN Incubator is a compact ... uses a microprocessor controller with a ... temperature and agitation speed. Air circulation ... the incubator. Temperature can be easily ...
    Biology Products: